Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004

Allison Hedley Dodd, Margaret S. Colby, Kristina S. Boye, Cheryl Fahlman, Sunny H Kim, Ronette R. Briefel

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To examine the distribution of diabetic medications among adults with type 2 diabetes, and the association between glucose control and treatment approach in the US population. Methods: Interview and prescription medication data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were used to determine the treatment approach for US adults with type 2 diabetes. Mean glycosylated hemoglobin (HbA1c) and the proportion of adults meeting recommended guidelines for glucose control were estimated for each treatment approach. The most important study limitation was that participants were not asked what type of diabetes they had. Among adults with diabetes, a classification algorithm was used to identify those with type 2 diabetes. Results: During 1999-2004, approximately 60% of adults with type 2 diabetes used oral agents only to manage their diabetes. The distribution of oral treatment therapies changed over time (p<0.01); the most prevalent treatment shifted from sulfonylurea monotherapy in 1999-2000 (23.0%) to any oral agent regimen containing thiazolidinedione (TZD) in 2003-2004 (21.4%). Overall, only 52.2% of adults with type 2 diabetes met the American Diabetes Association (ADA) goal for HbA1c control (<7.0%) during 1999-2004. Across oral agent treatment categories, the proportion with HbA1c controlled at the 7.0 level was significantly lower (p<0.01) for those on triple therapy (31.9%) (TZD, sulfonylurea, and metformin), than those on metformin alone (62.2%), likely reflecting a progressive treatment approach of prescribing additional medications for those with uncontrolled HbA1c levels. Conclusions: Use of multiple oral agents among adults with type 2 diabetes has increased (sulfonylurea and metformin, p = 0.03, triple therapy, p = 0.02). However, nearly half of adults with type 2 diabetes have HbA1c levels above ADA guidelines for control, indicating that available treatments could be used more optimally, and new diabetic agents may be needed.

Original languageEnglish (US)
Pages (from-to)1605-1613
Number of pages9
JournalCurrent Medical Research and Opinion
Volume25
Issue number7
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Nutrition Surveys
Type 2 Diabetes Mellitus
Metformin
Guidelines
Glucose
Glycosylated Hemoglobin A
Prescriptions
Therapeutics
Interviews
Population

Keywords

  • Glucose control
  • HbA
  • NHANES
  • Prescription medication
  • Treatment
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment approach and HbA1c control among US adults with type 2 diabetes : NHANES 1999-2004. / Dodd, Allison Hedley; Colby, Margaret S.; Boye, Kristina S.; Fahlman, Cheryl; Kim, Sunny H; Briefel, Ronette R.

In: Current Medical Research and Opinion, Vol. 25, No. 7, 07.2009, p. 1605-1613.

Research output: Contribution to journalArticle

Dodd, Allison Hedley ; Colby, Margaret S. ; Boye, Kristina S. ; Fahlman, Cheryl ; Kim, Sunny H ; Briefel, Ronette R. / Treatment approach and HbA1c control among US adults with type 2 diabetes : NHANES 1999-2004. In: Current Medical Research and Opinion. 2009 ; Vol. 25, No. 7. pp. 1605-1613.
@article{976519bd07264df794d686c7e8cfe248,
title = "Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004",
abstract = "Objective: To examine the distribution of diabetic medications among adults with type 2 diabetes, and the association between glucose control and treatment approach in the US population. Methods: Interview and prescription medication data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were used to determine the treatment approach for US adults with type 2 diabetes. Mean glycosylated hemoglobin (HbA1c) and the proportion of adults meeting recommended guidelines for glucose control were estimated for each treatment approach. The most important study limitation was that participants were not asked what type of diabetes they had. Among adults with diabetes, a classification algorithm was used to identify those with type 2 diabetes. Results: During 1999-2004, approximately 60{\%} of adults with type 2 diabetes used oral agents only to manage their diabetes. The distribution of oral treatment therapies changed over time (p<0.01); the most prevalent treatment shifted from sulfonylurea monotherapy in 1999-2000 (23.0{\%}) to any oral agent regimen containing thiazolidinedione (TZD) in 2003-2004 (21.4{\%}). Overall, only 52.2{\%} of adults with type 2 diabetes met the American Diabetes Association (ADA) goal for HbA1c control (<7.0{\%}) during 1999-2004. Across oral agent treatment categories, the proportion with HbA1c controlled at the 7.0 level was significantly lower (p<0.01) for those on triple therapy (31.9{\%}) (TZD, sulfonylurea, and metformin), than those on metformin alone (62.2{\%}), likely reflecting a progressive treatment approach of prescribing additional medications for those with uncontrolled HbA1c levels. Conclusions: Use of multiple oral agents among adults with type 2 diabetes has increased (sulfonylurea and metformin, p = 0.03, triple therapy, p = 0.02). However, nearly half of adults with type 2 diabetes have HbA1c levels above ADA guidelines for control, indicating that available treatments could be used more optimally, and new diabetic agents may be needed.",
keywords = "Glucose control, HbA, NHANES, Prescription medication, Treatment, Type 2 diabetes",
author = "Dodd, {Allison Hedley} and Colby, {Margaret S.} and Boye, {Kristina S.} and Cheryl Fahlman and Kim, {Sunny H} and Briefel, {Ronette R.}",
year = "2009",
month = "7",
doi = "10.1185/03007990902973300",
language = "English (US)",
volume = "25",
pages = "1605--1613",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Treatment approach and HbA1c control among US adults with type 2 diabetes

T2 - NHANES 1999-2004

AU - Dodd, Allison Hedley

AU - Colby, Margaret S.

AU - Boye, Kristina S.

AU - Fahlman, Cheryl

AU - Kim, Sunny H

AU - Briefel, Ronette R.

PY - 2009/7

Y1 - 2009/7

N2 - Objective: To examine the distribution of diabetic medications among adults with type 2 diabetes, and the association between glucose control and treatment approach in the US population. Methods: Interview and prescription medication data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were used to determine the treatment approach for US adults with type 2 diabetes. Mean glycosylated hemoglobin (HbA1c) and the proportion of adults meeting recommended guidelines for glucose control were estimated for each treatment approach. The most important study limitation was that participants were not asked what type of diabetes they had. Among adults with diabetes, a classification algorithm was used to identify those with type 2 diabetes. Results: During 1999-2004, approximately 60% of adults with type 2 diabetes used oral agents only to manage their diabetes. The distribution of oral treatment therapies changed over time (p<0.01); the most prevalent treatment shifted from sulfonylurea monotherapy in 1999-2000 (23.0%) to any oral agent regimen containing thiazolidinedione (TZD) in 2003-2004 (21.4%). Overall, only 52.2% of adults with type 2 diabetes met the American Diabetes Association (ADA) goal for HbA1c control (<7.0%) during 1999-2004. Across oral agent treatment categories, the proportion with HbA1c controlled at the 7.0 level was significantly lower (p<0.01) for those on triple therapy (31.9%) (TZD, sulfonylurea, and metformin), than those on metformin alone (62.2%), likely reflecting a progressive treatment approach of prescribing additional medications for those with uncontrolled HbA1c levels. Conclusions: Use of multiple oral agents among adults with type 2 diabetes has increased (sulfonylurea and metformin, p = 0.03, triple therapy, p = 0.02). However, nearly half of adults with type 2 diabetes have HbA1c levels above ADA guidelines for control, indicating that available treatments could be used more optimally, and new diabetic agents may be needed.

AB - Objective: To examine the distribution of diabetic medications among adults with type 2 diabetes, and the association between glucose control and treatment approach in the US population. Methods: Interview and prescription medication data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were used to determine the treatment approach for US adults with type 2 diabetes. Mean glycosylated hemoglobin (HbA1c) and the proportion of adults meeting recommended guidelines for glucose control were estimated for each treatment approach. The most important study limitation was that participants were not asked what type of diabetes they had. Among adults with diabetes, a classification algorithm was used to identify those with type 2 diabetes. Results: During 1999-2004, approximately 60% of adults with type 2 diabetes used oral agents only to manage their diabetes. The distribution of oral treatment therapies changed over time (p<0.01); the most prevalent treatment shifted from sulfonylurea monotherapy in 1999-2000 (23.0%) to any oral agent regimen containing thiazolidinedione (TZD) in 2003-2004 (21.4%). Overall, only 52.2% of adults with type 2 diabetes met the American Diabetes Association (ADA) goal for HbA1c control (<7.0%) during 1999-2004. Across oral agent treatment categories, the proportion with HbA1c controlled at the 7.0 level was significantly lower (p<0.01) for those on triple therapy (31.9%) (TZD, sulfonylurea, and metformin), than those on metformin alone (62.2%), likely reflecting a progressive treatment approach of prescribing additional medications for those with uncontrolled HbA1c levels. Conclusions: Use of multiple oral agents among adults with type 2 diabetes has increased (sulfonylurea and metformin, p = 0.03, triple therapy, p = 0.02). However, nearly half of adults with type 2 diabetes have HbA1c levels above ADA guidelines for control, indicating that available treatments could be used more optimally, and new diabetic agents may be needed.

KW - Glucose control

KW - HbA

KW - NHANES

KW - Prescription medication

KW - Treatment

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=67650472212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650472212&partnerID=8YFLogxK

U2 - 10.1185/03007990902973300

DO - 10.1185/03007990902973300

M3 - Article

C2 - 19469695

AN - SCOPUS:67650472212

VL - 25

SP - 1605

EP - 1613

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 7

ER -